Please select the option that best describes you:

What is the role of adjuvant radiation therapy for stage III melanoma in the era of adjuvant Opdivo?   

Burnmeister data from 2012 showed a local control benefit for radiation therapy in selected patients, but that was without immunotherapy. What specific clinico-pathologic factors (e.g., number of nodes, desmoplastic histology, primary site) guide your decision to recommending the addition of RT to standard-of-care immunotherapy, and how would you sequence therapy?



Answer from: Radiation Oncologist at Academic Institution
Comments
Radiation Oncologist at Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
I agree that the role of adjuvant radiation is unc...
Radiation Oncologist at Memorial Sloan Kettering Cancer Center
There is no singular policy that we uniformly adhe...
Radiation Oncologist at Christus St Vincent
What is your adjuvant dose and fractionation for r...
Sign in or Register to read more

Answer from: Radiation Oncologist at Academic Institution
Comments
Radiation Oncologist at University of Missouri at Columbia, Ellis Fischel Cancer Cener
interesting article. but it compared RT alone to S...
Radiation Oncologist at West Virginia University
I don't disagree with you about the likely benefit...
Sign in or Register to read more

Answer from: Radiation Oncologist at Academic Institution
Comments
Radiation Oncologist at Northeast Alabama Regional Medical Center
I just came here to say @Carl R. Bogardus was...
Radiation Oncologist at Yale School of Medicine
Agree whole heartedly. We sent flowers to his fami...
Sign in or Register to read more